论文部分内容阅读
去氧苯比妥是一种常用的抗惊厥药,在人体内转化为二种代谢物,苯巴比妥与苯乙基丙二酰胺。三种物质均有抗癫痫作用。去氧苯比妥治疗血浓范围为5～12μg/ml,常需进行临床监控。该药常与其它抗癫痫药合用以增强疗效,但药物的相互作用研究得较少。本文以血清去氧苯比妥及其代谢物苯巴比妥的两种物质的血清浓度与去氧苯比妥剂量比(L/D比值)为指标,评价了100例癫痫患者的联合用药情况。结果表明,在合用丙戊酸钠(或苯妥英)时,代谢
Hexamidine is a commonly used anticonvulsant that is converted into two metabolites in the human body, phenobarbital and phenethyl malonamide. Three substances have antiepileptic effect. Phenobarbital treatment of blood concentration range of 5 ~ 12μg / ml, often required for clinical monitoring. The drug is often used in combination with other antiepileptic drugs to enhance efficacy, but drug interactions are less studied. In this paper, the serum concentration of hexamidine and its metabolite phenobarbital in serum concentration and the ratio of hexamidine (L / D ratio) as an index to evaluate the combination of 100 cases of epilepsy patients . The results show that when combined with sodium valproate (or phenytoin), metabolism